Released Nov 9, 2015, after the close
10-Q filed Nov 9, 2015, 40 days after period end · 0001144204-15-063825
Q3 2015 · 10-Q
Revenue$1.34M$1.34M −44.2% vs Q3 2014±0.0% vs Q2 2015
Net Income-$3.82M-$3.82M N/M vs Q3 2014N/M vs Q2 2015
EPS Diluted-$0.04-$0.04 N/M vs Q3 2014N/M vs Q2 2015
Gross Profit$1,113,000−41.7%
Operating Income-$5,002,000N/M
Operating Cash Flowderived-$8,660,000N/M
Free Cash Flowderived-$8,788,000N/M
Margins · derived
Gross margin83.3%+3.6 pt vs Q3 2014
Operating margin-374.4%−115.3 pt vs Q3 2014
Net margin-285.9%+48.4 pt vs Q3 2014
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2015 | Q3 2014 | Q3 2013 | Q3 2012 |
|---|---|---|---|---|
| Revenue | $1.34M | $2.40M | $2.28M | $3.72M |
| Net Income | -$3.82M | -$8.01M | -$5.75M | -$5.48M |
| EPS Diluted | -$0.04 | -$0.09 | -$0.06 | $0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR